Last update: May 23, 2019
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
Antispasmodic drug used for treatment of Irritable Colon Syndrome and in the treatment of infant and young child vomiting (Pediamecum 2015).
At latest update, no relevant published data concerning excretion into breast milk were found.
Pharmacokinetic data support the likelihood of significant excretion into breast milk.
Side effects of Trimebutine are rare and generally mild (CADTH 2015, Paquette 2014).
Authorized use in some countries during the neonatal and infant period (Pediamecum 2015, Carnot 2008).
Anticholinergic drugs may reduce milk production. Use the minimal necessary dose as possible and avoid long-term use whenever a decrease in milk production would appear.
Occasional use and at a sufficient minimum dose may be compatible with breastfeeding. Monitor drowsiness and milk production.
Do not use it soon after birth or in case of premature infant.
We do not have alternatives for Trimebutine maleate.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM